Human rpL3 plays a crucial role in cell response to nucleolar stress induced by 5-FU and L-OHP

Recent evidence showed that a variety of DNA damaging agents including 5-FU and L-OHP impairs ribosomal biogenesis activating a ribosomal stress pathway. Here, we demonstrate that in lung and colon cancer cell lines devoid of p53, the efficacy of 5-FU and L-OHP chemotherapy depends on rpL3 status. Specifically, we demonstrate that ribosomal stress induced by 5-FU and L-OHP is associated to up-regulation of rpL3 and its accumulation as ribosome-free form. We show that rpL3 participates in the cell response to chemotherapy acting as a critical regulator of cell cycle, apoptosis and DNA repair, by modulating p21 expression. Moreover, we demonstrate that rpL3 is able to control DNA repair also independently from p21 status of cell. It is noteworthy that silencing of rpL3 abolishes the cytotoxic effects of 5-FU and L-OH indicating that the loss of rpL3 makes chemotherapy drugs ineffective. Taking together our results shed light on 5-FU and L-OHP mechanism of action and contribute to more effective clinical use of these drugs in cancer therapy.

[1]  S. Garattini,et al.  The pharmacological point of view of resistance to therapy in tumors. , 2014, Cancer treatment reviews.

[2]  M. Oren,et al.  p53 and ribosome biogenesis stress: The essentials , 2014, FEBS letters.

[3]  P. Pfeiffer,et al.  A systematic review of salvage therapy to patients with metastatic colorectal cancer previously treated with fluorouracil, oxaliplatin and irinotecan +/- targeted therapy. , 2014, Cancer treatment reviews.

[4]  S. Volarevic,et al.  Activation of the tumor suppressor p53 upon impairment of ribosome biogenesis. , 2014, Biochimica et biophysica acta.

[5]  R. Pearson,et al.  Targeting the nucleolus for cancer intervention. , 2014, Biochimica et biophysica acta.

[6]  K. O'Byrne,et al.  Chemotherapeutic Compounds Targeting the DNA Double-Strand Break Repair Pathways: The Good, the Bad, and the Promising , 2014, Front. Oncol..

[7]  Karen H. Vousden,et al.  Mutant p53 in Cancer: New Functions and Therapeutic Opportunities , 2014, Cancer cell.

[8]  D. V. Von Hoff,et al.  Targeting the nucleolus for cancer-specific activation of p53. , 2014, Drug discovery today.

[9]  R. Pearson,et al.  Targeting RNA polymerase I transcription and the nucleolus for cancer therapy , 2013, Expert opinion on therapeutic targets.

[10]  Giulia Russo,et al.  Discovery of a novel small molecule inhibitor targeting the frataxin/ubiquitin interaction via structure-based virtual screening and bioassays. , 2013, Journal of medicinal chemistry.

[11]  E. Crescenzi,et al.  Human rpL3 induces G₁/S arrest or apoptosis by modulating p21waf1/cip1 levels in a p53-independent manner , 2013, Cell cycle.

[12]  C. Prives,et al.  Mutual protection of ribosomal proteins L5 and L11 from degradation is essential for p53 activation upon ribosomal biogenesis stress , 2012, Proceedings of the National Academy of Sciences.

[13]  K. Mimori,et al.  A new PICTure of nucleolar stress , 2012, Cancer science.

[14]  J. Dahm-Daphi,et al.  In tumor cells regulation of DNA double strand break repair through EGF receptor involves both NHEJ and HR and is independent of p53 and K-Ras status. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[15]  Yanping Zhang,et al.  The RP-Mdm2-p53 Pathway and Tumorigenesis , 2011, Oncotarget.

[16]  E. Maccaroni,et al.  5-Fluorouracil pharmacogenomics: still rocking after all these years? , 2011, Pharmacogenomics.

[17]  S. Karlsson,et al.  PIM1 kinase is destabilized by ribosomal stress causing inhibition of cell cycle progression , 2010, Oncogene.

[18]  C. Deisenroth,et al.  Ribosome biogenesis surveillance: probing the ribosomal protein-Mdm2-p53 pathway , 2010, Oncogene.

[19]  M. Savio,et al.  Multiple roles of the cell cycle inhibitor p21(CDKN1A) in the DNA damage response. , 2010, Mutation research.

[20]  E. Kremmer,et al.  Chemotherapeutic Drugs Inhibit Ribosome Biogenesis at Various Levels* , 2010, The Journal of Biological Chemistry.

[21]  Yanping Zhang,et al.  Signaling to p53: ribosomal proteins find their way. , 2009, Cancer cell.

[22]  Anindya Dutta,et al.  p21 in cancer: intricate networks and multiple activities , 2009, Nature Reviews Cancer.

[23]  M. Wyatt,et al.  Participation of DNA repair in the response to 5-fluorouracil , 2009, Cellular and Molecular Life Sciences.

[24]  J. Leal,et al.  Loss-of-function genetic screening identifies a cluster of ribosomal proteins regulating p53 function. , 2008, Carcinogenesis.

[25]  Linda J. Kuo,et al.  γ-H2AX - A Novel Biomarker for DNA Double-strand Breaks , 2008 .

[26]  S. Elmore.  Apoptosis: A Review of Programmed Cell Death , 2007, Toxicologic pathology.

[27]  M. Dai,et al.  5-Fluorouracil Activation of p53 Involves an MDM2-Ribosomal Protein Interaction* , 2007, Journal of Biological Chemistry.

[28]  Yi-Tao Yu,et al.  Incorporation of 5-fluorouracil into U2 snRNA blocks pseudouridylation and pre-mRNA splicing in vivo , 2006, Nucleic acids research.

[29]  E. Kremmer,et al.  Dominant-negative Pes1 mutants inhibit ribosomal RNA processing and cell proliferation via incorporation into the PeBoW-complex , 2006, Nucleic acids research.

[30]  M. Cuccurese,et al.  Alternative splicing and nonsense-mediated mRNA decay regulate mammalian ribosomal gene expression , 2005, Nucleic acids research.

[31]  David J. Chen,et al.  Independent and sequential recruitment of NHEJ and HR factors to DNA damage sites in mammalian cells , 2005, The Journal of cell biology.

[32]  M. Dai,et al.  Ribosomal Protein L23 Activates p53 by Inhibiting MDM2 Function in Response to Ribosomal Perturbation but Not to Translation Inhibition , 2004, Molecular and Cellular Biology.

[33]  B. Baguley,et al.  Paclitaxel induces nucleolar enlargement in dorsal root ganglion neurons in vivo reducing oxaliplatin toxicity , 2003, British Journal of Cancer.

[34]  P. Johnston,et al.  5-Fluorouracil: mechanisms of action and clinical strategies , 2003, Nature Reviews Cancer.

[35]  L. Latonen,et al.  Cell cycle control, DNA damage checkpoints and cancer , 2003, Annals of medicine.

[36]  J. Misset,et al.  Oxaliplatin clinical activity: a review. , 2000, Critical reviews in oncology/hematology.

[37]  G. Casey,et al.  WAF1/CIP1 increases the susceptibility of p53 non-functional malignant glioma cells to cisplatin-induced apoptosis. , 1996, Oncogene.

[38]  C. Harris,et al.  Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. , 1994, Cancer research.

[39]  L. Montanaro,et al.  Changes in ribosome biogenesis may induce cancer by down-regulating the cell tumor suppressor potential. , 2012, Biochimica et biophysica acta.

[40]  Linda J. Kuo,et al.  Gamma-H2AX - a novel biomarker for DNA double-strand breaks. , 2008, In vivo.